Mizuho analyst Difei Yang views the recent selloff in shares of Zogenix as a buying opportunity. The analyst believes ZX008 in Lennox-Gastaut syndrom presents upside potential in 2019 and that Zogenix “is in comfortable position” to reach break-even following a recent $359M capital raise. Yang reiterates a Buy rating on the shares with a $69 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.